Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent’s IGF-1R Antibody Meets Endpoint for Thyroid Eye Disease

publication date: Feb 22, 2024

Suzhou Innovent (HK: 01801) reported that IBI31, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, met its endpoint in China Phase III trial in patients with Thyroid Eye Disease (TED). TED is an autoimmune disease that causes bulging eyes. A rare disease, the condition usually occurs in patients with Graves' disease (GD) and is the most common orbit-related (problems with the muscles and structures of the eye) disease in adults. TED occurs in approximately 25 to 50% of GD patients. Innovent, which developed the candidate for TED, plans to file an NDA for IBI311 in China.  More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital